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Breast cancer commonly metastasizes to bone in women with advanced disease to cause bone destruction and associated bone pain, fracture, hypercalcemia, and paralysis due to spinal cord compression. The most devastating consequence is that once breast cancer has spread to bone, it is incurable. Breast cancers mediate bone destruction by secreting factors that send the normal bone-resorbing cell, the osteoclast, into overdrive ( Figure 1 , osteolytic phase) (Weilbaecher et al., 2011; Roodman, 2004) . Bone destruction then releases growth factors stored in the mineralized matrix, such as transforming growth factor b (TGFb), that then increase tumor production of osteolytic factors and change tumor behavior to promote growth in bone.
This feed-forward cycle in the bone microenvironment has been the subject of intense research that has produced effective, but not curative, therapy for this catastrophic complication. Current therapy combines bone-targeted antiosteoclast agents (such as bisphosphonate zoledronic acid and RANK ligand inhibitor denosumab) with antitumor therapy. This standard of care improves skeletal morbidity but does not cure disease or have significant effects on survival. Currently, there are no effective predictors of who will develop bone metastases to guide long-term preventive therapy. In this issue of Cell, Zhang et al. (2013) implicate the microenvironment of the primary tumor as a determinant of bone metastases, at least in the case of triple-negative (TN) breast cancer. Specifically, cancerassociated fibroblasts (CAFs) in the primary tumor can influence tumor cells to develop the properties necessary to become successful bone metastases. This new understanding provides a mechanism that could lead to changes in the prognostic, predictive, and preventative management of women with advanced breast cancer and bone metastases.
The extensive study reveals an association of breast cancer bone metastasis with a gene expression signature (Src response signature, SRS) that denotes activation of Src and Src-dependent enhancement of PI3K-Akt signaling to CXCL12 and IGF1, particularly in TN breast cancers. TN breast cancer lacks expression of the estrogen receptor (ER), progesterone receptor, and HER2 and comprises about 15% of primary breast cancers but is overrepresented in patients with metastatic disease (Anders et al., 2013) . It is particularly aggressive, and unlike hormone-receptor-positive breast cancer, which often metastasizes to bone, TN breast cancer frequently metastasizes to nonbone sites. The present study focuses on a subset of TN breast cancer that metastasizes to bone and is characterized by a high level of Src activity and a high sensitivity to PI3K-Akt pathway activation by CXCL12 and IGF1 (Zhang et al., 2009) .
Currently, the use of chemotherapy and radiation does not differ significantly between early-stage TN and non-TN breast cancer (Anders et al., 2013) , but findings presented here, if born out in clinical trials, could shift that view. Indeed, SRS+ status is a strong predictor of bone metastases in TN breast cancer (Zhang et al., 2009) . Given that Src activation does not confer a growth advantage in primary breast cancer and that it is not mutated or amplified in breast cancer, the authors looked for mechanisms that lead to accumulation of Src-hyperactive cells in primary breast cancer. What they find in TN breast cancer is a stromadriven selection for breast cancer clones that are primed for bone metastases, a process governed by CXCL12 and IGF1 from mesenchymal stromal cells that selects for Src-hyperactive cancer cell clones that thrive in environments containing these signals (such as bone).
The authors examined primary human breast cancer and show that most ER+ and half of the HER2+ tumors have SRS+ signatures. SRS+ status is further shown to be a common downstream indicator of multiple mutations in PIK3CA in TN tumors. Then, by comparing SRSÀ and SRS+ TN tumors in independent clinical data sets (and focusing on genes that are enriched in SRS+ tumors but are not part of the SRS gene set itself), the authors reveal that CXCL12 and IGF1, among others, are also overexpressed in bone metastases tissues compared to other sites. Intriguingly, these cytokines are present in the bone marrow microenvironment where the tumors preferentially metastasize.
The source of these cytokines in the primary tumor is cancer associated (CAFs), and CAF content is associated with the propensity of TN tumors to metastasize to bone. Thus, the authors propose a ''metastasis seed preselection'' hypothesis and show that the selectable trait, Src hyperactivity, is present in the cancer cells where it is heterogeneously distributed. They use restrictive growth conditions to produce MDA-MB-231 breast cancer clones that grow in the presence of CXCL12 and IGF1. These clones (MDA231-CI) have Src hyperactivity that is not activated by CXCL12 or IGF1, but rather, these cytokines enhance the activation of the PI3K-Akt pathway, an effect that is blocked by the Src kinase inhibitor dasatinib. In vivo MDA231-CI causes more bone metastases when inoculated into the left cardiac ventricle or into the mammary fat pad. The latter is remarkable, as spontaneous bone metastases rarely occur from primary (mammary fat pad) breast tumors in mice.
In these in vivo studies, bone lesions formed by MDA231-CI are restricted to the bone marrow cavity and are not associated with increased osteoclast activity or bone destruction, compared with lesions from the aggressive bone metastatic MDA-MB-231 clone, MDA231-BoM1833 (Kang et al., 2003) , which exhibits massive bone destruction and osteoclast hyperactivity. Further, the MDA231-CI clones do not express the genes associated with bone metastases (Kang et al., 2003) , indicating that MDA231-CI clones spontaneously present a survival and growth advantage in the bone marrow, prior to the onset of the osteolytic stage.
Collectively, these elegant findings raise a number of questions. First, are these findings relevant in different breast cancers or other types of cancer? Next, CAFs make the primary tumor more like the bone site by producing CXCL12 and IGF1, which confers survival and growth advantage to establish at the bone site. However, in the present study, tumors at this ''preosteolytic'' stage do not produce osteolytic factors, stimulate osteoclast activity, or destroy bone. This raises the question of whether, in the MDA231-CI model, the tumors progress to an ''osteolytic phase'' as we observe in women with advanced breast cancer and bone metastases? If so, what mediates progression to the osteolytic phase? One possibility is the bone microenvironment; mineralized bone matrix is a rich storehouse of growth factors such as TGFb and IGF1 and 2 that can induce tumor expression of osteolytic factors such as PTHrP and IL-11 (Yin et al., 1999; Kang et al., 2003) (Figure 1) . What is the clinical relevance of the preosteolytic phase or the clinical evidence that this entity exists in women with TN breast cancer? Could a preosteolytic phase be detected by activity on PET scan without evidence of bone destruction? Will therapy directed against Src or the PI3K-Akt cell survival pathway be effective if the tumor is already in the osteolytic phase? Certainly, preclinical and small clinical trials show that Src inhibitors have antiosteoclast as well as antitumor activity in the setting of established bone metastases (Myoui et al., 2003; Rucci et al., 2006; Campone et al., 2012) Although the percentage of patients with bone-metastatic TN breast cancer is small, showing that the primary tumor stroma mediates a bone metastasis phenotype addresses the global concept of how organ-specific metastatic traits may arise. Obviously, the findings need to be confirmed in clinical trials as well as in other breast cancer types and different tumors. Regardless, any real estate broker will tell you that it is location, location, location and the neighborhood that determines the ultimate worth of a given home. Likewise, the neighborhood, or microenvironment, of a tumor cell can determine its ultimate destiny. In the case of the tumor cell, the primary tumor microenvironment may have as much influence on tumor behavior as that at the final metastatic destination. The conclusion is simple: the microenvironment matters. More importantly, it may dictate therapy. The findings presented here could change the general principles guiding the therapy of earlystage TN breast cancer and differentiate it from treatment of early-stage non-TN breast cancer. If clinical trials confirm the present findings, TN breast cancer Eventually, bone metastases become osteolytic and interact with the bone microenvironment to stimulate osteoclast activity via factors such as PTHrP, IL-11, and VEGF. The mechanism for the switch from ''preosteolytic'' to ''osteolytic'' stage is unclear and requires further investigation. Bone-derived factors, such as TGF-b, may be responsible by acting on the tumors to produce osteolytic factors and fuel a feed-forward cycle in the bone, which ultimately results in bone destruction.
patients with fibroblast-rich stroma in the primary tumor or with bone metastasis may benefit from therapies that target the PI3K-Akt cell survival pathway or its amplifier Src to prevent or treat bone metastases. Until such questions are addressed by prospective clinical trials, we will continue management of bone metastases with the combination of bone-targeted therapy as well as disease-specific therapy but will be optimistic that insight into the primary as well as the metastatic microenvironment will have profound implications to guide our future therapy.
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Proper chromosome segregation depends on correct attachments between microtubules and kinetochores. Budding yeast have been thought to achieve these attachments with different kinetics than other eukaryotes. Now, deploying specialized data processing techniques to achieve super-resolution images, Marco et al. demonstrate that this tractable cell-cycle model system shares more similarities with plants and animals than previously thought.
Dividing eukaryotic cells face a universal challenge-in order to deliver duplicated chromosomes to separate daughter cells, they must establish stable connections between a pair of sister kinetochores residing on each mitotic chromosome and microtubules of the mitotic spindle. This process, known as chromosome biorientation, involves molecular machines and regulatory feedback circuits that are conserved throughout all simple and complex eukaryotes. Malformed attachments, such as when a pair of kinetochores attach to the same pole (''syntelic'' attachments), cannot properly segregate, and result in aneuploidy, are linked to birth defects and cancer promotion in animals and humans. Several model systems are used to study mitosis, with S. cerevisiae being one of the most powerful and popular. Unlike most animal and plant cells, this budding yeast uses a closed mitosis where the nuclear envelope remains intact throughout M phase. The spindle pole body (SPB) is embedded in the nuclear envelope and nucleates intranuclear microtubules that attach to kinetochores throughout the cell cycle. A prevailing view has been that biorientation occurs early in budding yeast, before M phase, as opposed to biorientation in animal and plant cells that occurs gradually throughout M phase in an apparently random cycle of microtubule-kinetochore destabilization and reattachment. In this issue of Cell, Marco et al. (2013) revisit this issue by directly imaging yeast kinetochores during chromosome biorientation. They are by no means the first to make such a measurement, but their approach is the most comprehensive and direct to date, and their results clarify
